A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer
Stage IIIA-N2 non-small cell lung cancer (NSCLC) is a heterogeneous group with different potential therapeutic approaches. Treatment is typically multimodal with either surgical resection after neoadjuvant chemotherapy and/or radiation or concurrent chemotherapy and radiation if unresectable. Despit...
Main Authors: | Madeleine B. Hopson, Sawsan Rashdan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1373388/full |
Similar Items
-
The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
by: Anjali Kalra, et al.
Published: (2023-04-01) -
Multimodal Treatment of a Canine Lingual Melanoma Using a Combination of Immunotherapy and a Tyrosine Kinase Inhibitors
by: Alexander Berry, et al.
Published: (2022-01-01) -
Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience
by: Izabela Chmielewska, et al.
Published: (2021-10-01) -
Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials
by: Marco de Scordilli, et al.
Published: (2022-06-01) -
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
by: Qinlian Jiao, et al.
Published: (2018-02-01)